|
Faculty | |
Statement of Need | |
Learning Objectives | |
Financial Support | |
Target Audience | |
Credit Information |
Breaking the Burden: Assessing and Improving Quality of Life in Patients with CRSwNP
Premiere Date: Friday, April 22, 2022This activity offers CE credit for:
%>- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Saturday, April 22, 2023
Note: Credit Is No Longer Available
Joseph K. Han, MD, FARS, FAAAAI (Moderator) Professor Chief, Division of Rhinology & Endoscopic Sinus and Skull Base Surgery Chief, Division of Allergy Eastern Virginia Medical School Norfolk, VA ARS, Immediate Past President AAAAI, RROAC, Chair |
Stella Lee, MD Section Chief, Rhinology Division of Otolaryngology-Head & Neck Surgery Brigham and Women's Hospital Harvard Medical School Boston, MA |
Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a chronic inflammatory disease characterized by rhinosinusitis and the development of polyposis originating in the sinus and eventually extending to the nose. Persistent symptoms include congestion, stuffiness, nasal discharge, facial pain and/or pressure, impairment, or loss of sense of smell, and fatigue. CRSwNP confers a substantial but often underappreciated burden, negatively impacting mental and physical health-related quality of life (HRQoL) endpoints. To help alleviate this burden clinicians need to recognize the impact of CRSwNP and its many comorbidities on patients’ HRQoL and understand how the severity of CRSwNP can affect treatment response and duration.
In part one of this CMEO Snack series on CRSwNP, join Dr. Han and Dr. Lee as they discuss strategies for how clinicians can better recognize and understand the impact of the burden posed by CRSwNP.
At the end of this CE activity, participants should be able to:
- Recognize the burden of CRSwNP and the impact of this disease on patients' HRQoL and treatment response.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.
Physicians, PAs, nurse practitioners, nurses and pharmacists specializing in allergy/immunology, and otolaryngology practicing globally
ABIM MOC:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
UEMS-EACCME:
Through a mutual recognition agreement between the AMA and the UEMS-EACCME, European physicians completing an e-learning activity from a US-based ACCME-accredited CME provider can use AMA PRA Category 1 Credit™ toward their credit requirements. CME Outfitters is based in Radnor, Pennsylvania, USA. Please retain your certificate as proof of completion.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Dr. Han reports the following financial relationships:
Research Support: AstraZeneca; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; and Sanofi Genzyme
Dr. Lee reports the following financial relationships:
Consultant and Research Support: AstraZeneca; Genentech, Inc.; Novartis Pharmaceuticals Corporation; GlaxoSmithKline; and Sanofi Regeneron
The following peer reviewer and CME Outfitters staff have no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
SN-161-042222-90